Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 6/2012

01-06-2012 | Editorial

Osteopontin Biomarker in Inflammatory Bowel Disease, Animal Models and Target for Drug Discovery

Author: Manuela G. Neuman

Published in: Digestive Diseases and Sciences | Issue 6/2012

Login to get access

Excerpt

Inflammatory bowel disease (IBD) is an immune-mediated disease caused by abnormal mucosal T-cell response to bacteria in the intestinal lumen. In Crohn’s disease (CD), mucosal T cells exhibit the TH1 phenotype, whereas ulcerative colitis (UC) is believed to have a TH2 phenotype [1]. …
Literature
1.
Neuman MG. Immune dysfunction in inflammatory bowel disease. Trans Res. 2007;149:173–186.CrossRef
2.
Ullman TA, Palmon R. The certain uncertainty of measuring disease activity in IBD. J Clin Gastroenterol. 2007;41:123–125.PubMedCrossRef
3.
Meuwis MA, Fillet M, Geurts P, et al. Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling. Biochem Pharmacol. 2007;73:1422–1433.PubMedCrossRef
4.
Glas J, Seiderer J, Bayrle C, et al. The role of osteopontin (OPN/SPP1) haplotypes in the susceptibility to Crohn’s disease. PLoS ONE. 2011;6:e29309.PubMedCrossRef
5.
Mishima R, Takeshima F, Sawai T, et al. High plasma osteopontin levels in patients with inflammatory bowel disease. J Clin Gastroenterol. 2007;41:167–172.PubMedCrossRef
6.
Masuda H, Takahashi Y, Asai S, Hemmi A, Takayama T. Osteopontin expression in ulcerative colitis is distinctly different from that in Crohn’s disease and diverticulitis. J Gastroenterol. 2005;40:409–413.PubMedCrossRef
7.
Masuda H, Takahashi Y, Asai S, Takayama T. Distinct gene expression of osteopontin in patients with ulcerative colitis. J Surg Res. 2003;111:85–90.PubMedCrossRef
8.
Hong Q, Dvorak AM. Ultrastructural localization of osteopontin immunoreactivity in phagolysosomes and secretory granules of cells in human intestine. Histochem J. 1997;29:801–812.CrossRef
9.
Gassler N, Autschbach F, Gauer S, et al. Expression of osteopontin (Eta-1) in Crohn disease of the terminal ileum. Scand J Gastroenterol. 2002;37:1286–1295.PubMedCrossRef
10.
Sato T, Nakai T, Tamura N, et al. Osteopontin/Eta-1 upregulated in Crohn’s disease regulates the Th1 immune response. Gut. 2005;54:1254–1262.PubMedCrossRef
11.
Ashkar S, Weber GF, Panoutsakopoulou V, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science. 2000;287:860–864.PubMedCrossRef
12.
Gordon JN, MacDonald TT. Osteopontin: a new addition to the constellation of cytokines which drive T helper cell type 1 responses in Crohn’s disease. Gut. 2005;54:1213–1215.PubMedCrossRef
13.
Briskin M, Winsor-Hines D, Shyjan A, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathology. 1997;151:97–110.
14.
Jones SC, Banks RE, Haidar A, et al. Adhesion molecules in inflammatory bowel disease. Gut. 1995;36:724–730.PubMedCrossRef
15.
Podolsky KD, Lobb R, King N, et al. Attention of colitis in the cotton-top tamarin by anti-α4 integrin monoclonal antibody. J Clin Invest. 1993;92:372–380.PubMedCrossRef
16.
Hesterberg P, Windsor-Hines D, Briskin M, et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a Gut-Homing Integrin α4β7. Gastroenterology. 1996;111:1373–1380.PubMedCrossRef
17.
Rieder F, Fiocchi C. Intestinal fibrosis in inflammatory bowel disease: progress in basic and clinical science. Curr Opin Gastroenterol. 2008;24:462–468.PubMedCrossRef
18.
Agnholt J, Kelsen J, Schack L, Hvas CL, Dahlerup JF, Sørensen ES. Osteopontin, a protein with cytokine-like properties, is associated with inflammation in Crohn’s disease. Scand J Immunol. 2007;65:453–460.PubMedCrossRef
19.
Wine E, Shen-Tu G, Gareau MG, et al. Osteopontin mediates Citrobacter rodentium-induced colonic epithelial cell hyperplasia and attaching-effacing lesions. Am J Pathol. 2010;177:1320–1332.PubMedCrossRef
20.
Oz HS, Chen TS, Nagasawa H. Comparative efficacies of 2 cysteine prodrugs and a glutathione delivery agent in a colitis model. Trans Res. 2007;150:122–129.CrossRef
21.
Zhong J, Eckhardt ER, Oz HS, Bruemmer D, de Villiers WJ. Osteopontin deficiency protects mice from Dextran sodium sulfate-induced colitis. Inflamm Bowel Dis. 2006;12:790–796.PubMedCrossRef
22.
Da Silva AP, Pollett A, Rittling SR, Denhardt DT, Sodek J, Zohar R. Exacerbated tissue destruction in DSS-induced acute colitis of OPN-null mice is associated with downregulation of TNF-alpha expression and non-programmed cell death. J Cell Physiol. 2006;208:629–639.PubMedCrossRef
23.
Fan K, Zhang B, Yang H, et al. A humanized anti-osteopontin antibody protects from Concanavalin A induced-liver injury in mice. Eur J Pharmacol. 2011;657:144–151.PubMedCrossRef
24.
Metadata
Title
Osteopontin Biomarker in Inflammatory Bowel Disease, Animal Models and Target for Drug Discovery
Author
Manuela G. Neuman
Publication date
01-06-2012
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 6/2012
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-012-2120-9

Other articles of this Issue 6/2012

Digestive Diseases and Sciences 6/2012 Go to the issue

Original Article

Liver Stiffness Measurement Using Acoustic Radiation Force Impulse (ARFI) Elastography and Effect of Necroinflammation

Correspondence

Incidence of Propofol Injection Pain and Effect of Lidocaine Pretreatment During Upper Gastrointestinal Endoscopy

Original Article

Prognostic Significance of High Phosphatase of Regenerating Liver-3 Expression in Patients with Gastric Cancer Who Underwent Curative Gastrectomy

Original Article

Upper Gastrointestinal Involvement of Crohn’s Disease: A Prospective Study on the Role of Upper Endoscopy in the Diagnostic Work-Up

Perspective

Time to Rethink Antiviral Treatment for Hepatitis C in Patients with Coexisting Mental Health/Substance Abuse Issues

Editorial

Hydrogen Sulfide: A Rescue Molecule for Mucosal Defence and Repair
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits